Don't forget to register for the seminar on An overview of the Phase 1 Trial of TPI-287/Temezolomide in Neuroblastoma and Medulloblastoma tomorrow.
Dr. Giselle Sholler, principal investigator and pediatric oncologist from Vermont Cancer Center, will be presenting important information regarding the newly opened "Phase 1 Trial of TPI 287 as a Single Agent and in Combination with Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma." This presentation is intended for parents and caregivers of children with refractory or recurrent neuroblastoma and medulloblastoma. Dr. Sholler will provide an overview of the preclinical research leading up to the trial. She will also be discussing the rationale behind the trial, the purpose of the study, and the eligibility requirements. Dr. Sholler will share a summary of the treatment plan and delve into some of the patient experiences that have been seen previously. Parents of children that have participated in this trial will also be available to share their experiences. The presentation will be followed with a question and answer session. Participation in this online seminar will provide you with the information necessary to aid your and your child’s oncologist in deciding whether this trial may or may not be appropriate for your child. Please join us for the hour long presentation and question and answer session on Wednesday, August 26, 2009 at 12:00PM CST.
After registering you will receive a confirmation email containing information about joining the Webinar.
Space is limited.Reserve your Webinar seat now at:https://www2.gotomeeting.com/register/601120458
With hope,
Mark Dungan - father to Sydney (dx 6/21/2003 at age 2, stage 4 neuroblastoma, nmyc amplified, completed A3973, completed ANBL0032, 3F8, Nestle vaccine, currently NED), Graham, and Ainsley
Nitrofurantoin 100mg - Macrodantin 100mg
Click Here To Enter
Generic: nitrofurantoin